Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
CNS Pharmaceuticals initiated with a Buy at Alliance Global Partners » 07:04
08/27/21
08/27
07:04
08/27/21
07:04
CNSP

CNS Pharmaceuticals

$1.64 /

-0.02 (-1.21%)

Alliance Global Partners…

Alliance Global Partners analyst Matt Cross initiated coverage of CNS Pharmaceuticals with a Buy rating and $4 price target. The company is is developing a CNS-penetrant anthracycline chemotherapy called berubicin for the treatment of recurrent glioblastoma multiforme, Cross tells investors in a research note. Berubicin's forthcoming data readouts in the indication could consequently send the "shares soaring if our triangulation is correct," says the analyst.

ShowHide Related Items >><<
CNSP CNS Pharmaceuticals
$1.64 /

-0.02 (-1.21%)

CNSP CNS Pharmaceuticals
$1.64 /

-0.02 (-1.21%)

06/29/21 Benchmark
CNS' Fast Track Designation further de-risks berubicin, says Benchmark
02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
  • 23
    Dec
Over a month ago
Hot Stocks
CNS Pharmaceuticals sees cash on hand sufficient into 2Q22  08:10
08/13/21
08/13
08:10
08/13/21
08:10
CNSP

CNS Pharmaceuticals

$1.63 /

-0.02 (-1.21%)

 
ShowHide Related Items >><<
CNSP CNS Pharmaceuticals
$1.63 /

-0.02 (-1.21%)

CNSP CNS Pharmaceuticals
$1.63 /

-0.02 (-1.21%)

06/29/21 Benchmark
CNS' Fast Track Designation further de-risks berubicin, says Benchmark
02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
  • 23
    Dec
Hot Stocks
WPD says CNS Pharmaceuticals receives Fast Track Designation for berubicin » 07:35
07/12/21
07/12
07:35
07/12/21
07:35
WPDPF

WPD Pharmaceuticals

/

+

, CNSP

CNS Pharmaceuticals

$1.84 /

+0.03 (+1.66%)

WPD Pharmaceuticals…

WPD Pharmaceuticals (WPDPF) announced that CNS Pharmaceuticals (CNSP), the company that licenses the drug candidate Berubicin to WPD for 29 countries mainly in Europe, announced that the U.S. Food and Drug Administration granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme. As previously reported, CNS had also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM. CNS recently announced the start of patient enrollment in its study of Berubicin for the treatment of recurrent glioblastoma multiforme. WPD would significantly benefit from advancement of Berubicin as a treatment for GBM as it has the rights to produce and sell the drug candidate in 29 countries.

ShowHide Related Items >><<
WPDPF WPD Pharmaceuticals
/

+

CNSP CNS Pharmaceuticals
$1.84 /

+0.03 (+1.66%)

WPDPF WPD Pharmaceuticals
/

+

CNSP CNS Pharmaceuticals
$1.84 /

+0.03 (+1.66%)

06/29/21 Benchmark
CNS' Fast Track Designation further de-risks berubicin, says Benchmark
02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
  • 23
    Dec
Recommendations
CNS' Fast Track Designation further de-risks berubicin, says Benchmark » 11:10
06/29/21
06/29
11:10
06/29/21
11:10
CNSP

CNS Pharmaceuticals

$2.12 /

+0.11 (+5.47%)

After CNS Pharmaceuticals…

After CNS Pharmaceuticals announced that it has received FDA Fast Track Designation for berubicin to treat Glioblastoma Multiforme, Benchmark analyst Bruce Jackson said the designation further de-risks the program when combined with the adaptive design of the company's Phase 2 study. The analyst, who sees interim data from studies expected during 2022 as the next catalysts for the stock, has a Speculative Buy rating and $8 price target on CNS Pharmaceuticals shares.

ShowHide Related Items >><<
CNSP CNS Pharmaceuticals
$2.12 /

+0.11 (+5.47%)

CNSP CNS Pharmaceuticals
$2.12 /

+0.11 (+5.47%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
  • 23
    Dec
Hot Stocks
CNS Pharmaceuticals granted FDA Fast Track Designation for Berubicin » 08:36
06/29/21
06/29
08:36
06/29/21
08:36
CNSP

CNS Pharmaceuticals

$2.01 /

-0.03 (-1.47%)

CNS Pharmaceuticals…

CNS Pharmaceuticals announced that the U.S. FDA granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme. As previously reported, the company has also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM.

ShowHide Related Items >><<
CNSP CNS Pharmaceuticals
$2.01 /

-0.03 (-1.47%)

CNSP CNS Pharmaceuticals
$2.01 /

-0.03 (-1.47%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
  • 23
    Dec
Hot Stocks
WPD Pharmaceuticals plans to commence Phase 1b/II study of berubicin » 07:34
06/28/21
06/28
07:34
06/28/21
07:34
WPDPF

WPD Pharmaceuticals

/

+

, CNSP

CNS Pharmaceuticals

$2.04 /

-0.02 (-0.97%)

WPD Pharmaceuticals…

WPD Pharmaceuticals provided an update on its Berubicin drug candidate clinical development program for the treatment of glioblastoma multiforme. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin's Phase I clinical trial in adults, the first time it was tested in humans, yielded promising results with 44% of the patients with glioblastoma multiforme showing a clinical response of stable disease or better based on limited clinical data. This response rate rises to 49% in Avastin-naive patients. Importantly, Berubicin has shown evidence of improved overall survival in a patient population that currently has a dismal median survival rate of only 14.6 months from diagnosis. WPD expects final approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products shortly and anticipates starting a Phase II Trial in the second half of 2021. Based on the promising Phase I results, WPD plans to commence a multicenter, open-label, Phase Ib/II efficacy, and safety study of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy of a single arm of Berubicin treatment, administered at the recommended Phase II dose identified in the Phase I study, on the endpoint of Overall Response Rate in up to approximately 61 patients with GBM. The trials will include an interim analysis of the first 18 patients in the first half of 2022 for efficacy and safety as well as an extensive pharmacokinetic profile for these patients. WPD is planning the Phase I clinical trial for malignant gliomas at two clinical sites in Poland. The study includes a multicenter, open-label, dose escalation Phase I study of intravenous Berubicin in pediatric patients. The purpose of this first-in-pediatrics study is to examine the safety, tolerability, and pharmacokinetics of Berubicin and to estimate its MTD and/or RP2D when administered to pediatric patients with progressive, refractory, or recurrent HGG who have completed at least 1 standard line of therapy. This study will also make a preliminary assessment of the antitumor activity of Berubicin in this patient population in up to approximately 35 patients. This Phase I trial of Berubicin represents the first ever investigation of Berubicin in pediatric brain tumors. WPD has already received Ethical Committee approval for Phase I clinical trial and has submitted its request for approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Information on approval and study number in European clinical trials database will be provided within 60 days. WPD expects to commence the Phase I clinical trial in Q3/Q4 2021. CNS Pharmaceuticals (CNSP), the company that sublicenses the compound Berubicin to WPD for 30 countries mainly in Europe and Asia, announced open enrollment in the United States for its clinical study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. CNS's potentially pivotal trial is an adaptive, multicenter, open-label, randomized and controlled study in adult patients with recurrent glioblastoma multiforme after failure of standard first-line therapy. The primary endpoint of the study is Overall Survival. Overall Survival is a rigorous endpoint that the U.S. Food and Drug Administration has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. Results from the trial will compare Berubicin to the current standard of care, with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine.

ShowHide Related Items >><<
WPDPF WPD Pharmaceuticals
/

+

CNSP CNS Pharmaceuticals
$2.04 /

-0.02 (-0.97%)

WPDPF WPD Pharmaceuticals
/

+

CNSP CNS Pharmaceuticals
$2.04 /

-0.02 (-0.97%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
  • 23
    Dec
Over a quarter ago
Hot Stocks
CNS Pharmaceuticals begins patient enrollment in Berubicin study for GBM » 08:09
05/19/21
05/19
08:09
05/19/21
08:09
CNSP

CNS Pharmaceuticals

$1.87 /

+0.07 (+3.89%)

CNS Pharmaceuticals…

CNS Pharmaceuticals announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme. CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of a number of serious brain and CNS oncology indications. The company intends to enroll approximately 210 subjects across 35 clinical sites in the U.S. and also plans to expand the trial into western Europe. The primary endpoint of the study is Overall Survival. Overall Survival is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. Results from the trial will compare Berubicin to the current standard of care. In addition, sublicensee partner in Poland, WPD Pharmaceuticals, will initiate a Phase 2 multicenter clinical trial of Berubicin in adult GBM in the second half of 2021 as well as a Phase 1 multicenter clinical trial of Berubicin in pediatric gliomas in 2021. The FDA has granted CNS Pharmaceuticals Orphan Drug Designation for Berubicin, which provides seven years of marketing exclusivity upon approval of an NDA. CNS Pharmaceuticals intends to file for additional patents relating to Berubicin to further secure intellectual property protections.

ShowHide Related Items >><<
CNSP CNS Pharmaceuticals
$1.87 /

+0.07 (+3.89%)

CNSP CNS Pharmaceuticals
$1.87 /

+0.07 (+3.89%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
  • 23
    Dec
Conference/Events
Investor Summit Group to hold a virtual summit » 04:55
05/18/21
05/18
04:55
05/18/21
04:55
AEZS

Aeterna Zentaris

/

+

, BIOX

Bioceres

$15.78 /

+0.43 (+2.80%)

, CNSP

CNS Pharmaceuticals

$1.82 /

+0.02 (+1.11%)

, DTSS

Datasea

$2.61 /

-0.035 (-1.32%)

, FLY

Fly Leasing

$16.91 /

-0.04 (-0.24%)

, GOVX

GeoVax Labs

$5.20 /

-0.02 (-0.38%)

, GBOX

GreenBox

$9.26 /

+1.02 (+12.38%)

, PFMT

Performant Financial

$2.08 /

-0.03 (-1.42%)

, MNTX

Manitex

$7.30 /

+0.02 (+0.27%)

, MACE

Mace Security

/

+

, KTRA

Kintara Therapeutics

$1.26 /

-0.025 (-1.95%)

, NSPR

InspireMD

$4.59 /

+0.01 (+0.22%)

, SING

SinglePoint

/

+

, TNXP

Tonix Pharmaceuticals

$1.05 /

-0.02 (-1.88%)

, URG

Ur-Energy

$1.50 /

+0.1 (+7.17%)

, VLON

Vallon Pharmaceuticals

$3.69 /

+0.05 (+1.37%)

, SPI

SPI Energy

$5.22 /

+0.09 (+1.75%)

, EDT

Entergy Texas

/

+

, XBIO

Xenetic

$1.78 /

+0.11 (+6.59%)

Q2 Virtual Summit will be…

Q2 Virtual Summit will be held on May 17-18.Webcast Link

ShowHide Related Items >><<
XBIO Xenetic
$1.78 /

+0.11 (+6.59%)

VLON Vallon Pharmaceuticals
$3.69 /

+0.05 (+1.37%)

URG Ur-Energy
$1.50 /

+0.1 (+7.17%)

TNXP Tonix Pharmaceuticals
$1.05 /

-0.02 (-1.88%)

SPI SPI Energy
$5.22 /

+0.09 (+1.75%)

SING SinglePoint
/

+

PFMT Performant Financial
$2.08 /

-0.03 (-1.42%)

NSPR InspireMD
$4.59 /

+0.01 (+0.22%)

MNTX Manitex
$7.30 /

+0.02 (+0.27%)

KTRA Kintara Therapeutics
$1.26 /

-0.025 (-1.95%)

GOVX GeoVax Labs
$5.20 /

-0.02 (-0.38%)

GBOX GreenBox
$9.26 /

+1.02 (+12.38%)

FLY Fly Leasing
$16.91 /

-0.04 (-0.24%)

DTSS Datasea
$2.61 /

-0.035 (-1.32%)

CNSP CNS Pharmaceuticals
$1.82 /

+0.02 (+1.11%)

BIOX Bioceres
$15.78 /

+0.43 (+2.80%)

AEZS Aeterna Zentaris
/

+

AEZS Aeterna Zentaris
/

+

BIOX Bioceres
$15.78 /

+0.43 (+2.80%)

04/08/21 Lake Street
Bioceres price target raised to $20 from $15 at Lake Street
03/15/21 Lake Street
Bioceres initiated with a Buy at Lake Street
CNSP CNS Pharmaceuticals
$1.82 /

+0.02 (+1.11%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
DTSS Datasea
$2.61 /

-0.035 (-1.32%)

FLY Fly Leasing
$16.91 /

-0.04 (-0.24%)

04/05/21 Cowen
Fly Leasing downgraded to Market Perform from Outperform at Cowen
04/01/21 JPMorgan
JPMorgan downgrades Fly Leasing to Underweight after takeover announcement
04/01/21 JPMorgan
Fly Leasing downgraded to Underweight from Overweight at JPMorgan
03/19/21 Deutsche Bank
Fly Leasing price target raised to $13 from $10 at Deutsche Bank
GOVX GeoVax Labs
$5.20 /

-0.02 (-0.38%)

11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
GBOX GreenBox
$9.26 /

+1.02 (+12.38%)

PFMT Performant Financial
$2.08 /

-0.03 (-1.42%)

MNTX Manitex
$7.30 /

+0.02 (+0.27%)

11/19/20 Roth Capital
Manitex resumed with a Buy at Roth Capital
MACE Mace Security
/

+

KTRA Kintara Therapeutics
$1.26 /

-0.025 (-1.95%)

09/14/20 Aegis
Kintara Therapeutics initiated with a Buy at Aegis
NSPR InspireMD
$4.59 /

+0.01 (+0.22%)

10/16/20 Alliance Global Partners
InspireMD initiated with a Buy at Alliance Global Partners
SING SinglePoint
/

+

TNXP Tonix Pharmaceuticals
$1.05 /

-0.02 (-1.88%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
URG Ur-Energy
$1.50 /

+0.1 (+7.17%)

04/19/21 Alliance Global Partners
Ur-Energy initiated with a Buy at Alliance Global Partners
03/26/21 H.C. Wainwright
Ur-Energy price target raised to $2.10 from $1.40 at H.C. Wainwright
12/14/20 Cantor Fitzgerald
Cameco downgraded to Hold from Buy at Cantor Fitzgerald
VLON Vallon Pharmaceuticals
$3.69 /

+0.05 (+1.37%)

SPI SPI Energy
$5.22 /

+0.09 (+1.75%)

EDT Entergy Texas
/

+

XBIO Xenetic
$1.78 /

+0.11 (+6.59%)

01/11/21 H.C. Wainwright
Xenetic price target raised to $5 from $2 at H.C. Wainwright
VLON Vallon Pharmaceuticals
$3.69 /

+0.05 (+1.37%)

TNXP Tonix Pharmaceuticals
$1.05 /

-0.02 (-1.88%)

KTRA Kintara Therapeutics
$1.26 /

-0.025 (-1.95%)

FLY Fly Leasing
$16.91 /

-0.04 (-0.24%)

BIOX Bioceres
$15.78 /

+0.43 (+2.80%)

AEZS Aeterna Zentaris
/

+

  • 17
    Feb
  • 17
    Feb
  • 04
    Feb
  • 10
    Feb
  • 23
    Dec
  • 01
    Oct
  • 25
    Sep
GBOX GreenBox
$9.26 /

+1.02 (+12.38%)

FLY Fly Leasing
$16.91 /

-0.04 (-0.24%)

VLON Vallon Pharmaceuticals
$3.69 /

+0.05 (+1.37%)

TNXP Tonix Pharmaceuticals
$1.05 /

-0.02 (-1.88%)

SPI SPI Energy
$5.22 /

+0.09 (+1.75%)

GBOX GreenBox
$9.26 /

+1.02 (+12.38%)

FLY Fly Leasing
$16.91 /

-0.04 (-0.24%)

BIOX Bioceres
$15.78 /

+0.43 (+2.80%)

SPI SPI Energy
$5.22 /

+0.09 (+1.75%)

PFMT Performant Financial
$2.08 /

-0.03 (-1.42%)

GBOX GreenBox
$9.26 /

+1.02 (+12.38%)

BIOX Bioceres
$15.78 /

+0.43 (+2.80%)

AEZS Aeterna Zentaris
/

+

Conference/Events
Investor Summit Group to hold a virtual summit » 09:56
05/17/21
05/17
09:56
05/17/21
09:56
AEZS

Aeterna Zentaris

/

+

, BIOX

Bioceres

$15.76 /

+0.41 (+2.67%)

, CNSP

CNS Pharmaceuticals

$1.79 /

-0.01 (-0.56%)

, DTSS

Datasea

$2.65 /

+0.005 (+0.19%)

, FLY

Fly Leasing

$16.93 /

-0.02 (-0.12%)

, GOVX

GeoVax Labs

$5.21 /

-0.01 (-0.19%)

, GBOX

GreenBox

$8.35 /

+0.11 (+1.33%)

, PFMT

Performant Financial

$2.10 /

-0.01 (-0.47%)

, MNTX

Manitex

$7.28 /

+ (+0.00%)

, MACE

Mace Security

/

+

, KTRA

Kintara Therapeutics

$1.30 /

+0.015 (+1.17%)

, NSPR

InspireMD

$4.67 /

+0.09 (+1.97%)

, SING

SinglePoint

/

+

, TNXP

Tonix Pharmaceuticals

$1.06 /

-0.005 (-0.47%)

, URG

Ur-Energy

$1.45 /

+0.05 (+3.58%)

, VLON

Vallon Pharmaceuticals

$3.67 /

+0.03 (+0.82%)

, SPI

SPI Energy

$5.35 /

+0.22 (+4.29%)

, EDT

Entergy Texas

/

+

, XBIO

Xenetic

$1.68 /

+0.01 (+0.60%)

Q2 Virtual Summit will be…

Q2 Virtual Summit will be held on May 17-18.Webcast Link

ShowHide Related Items >><<
XBIO Xenetic
$1.68 /

+0.01 (+0.60%)

VLON Vallon Pharmaceuticals
$3.67 /

+0.03 (+0.82%)

URG Ur-Energy
$1.45 /

+0.05 (+3.58%)

TNXP Tonix Pharmaceuticals
$1.06 /

-0.005 (-0.47%)

SPI SPI Energy
$5.35 /

+0.22 (+4.29%)

SING SinglePoint
/

+

PFMT Performant Financial
$2.10 /

-0.01 (-0.47%)

NSPR InspireMD
$4.67 /

+0.09 (+1.97%)

MNTX Manitex
$7.28 /

+ (+0.00%)

KTRA Kintara Therapeutics
$1.30 /

+0.015 (+1.17%)

GOVX GeoVax Labs
$5.21 /

-0.01 (-0.19%)

GBOX GreenBox
$8.35 /

+0.11 (+1.33%)

FLY Fly Leasing
$16.93 /

-0.02 (-0.12%)

DTSS Datasea
$2.65 /

+0.005 (+0.19%)

CNSP CNS Pharmaceuticals
$1.79 /

-0.01 (-0.56%)

BIOX Bioceres
$15.76 /

+0.41 (+2.67%)

AEZS Aeterna Zentaris
/

+

AEZS Aeterna Zentaris
/

+

BIOX Bioceres
$15.76 /

+0.41 (+2.67%)

04/08/21 Lake Street
Bioceres price target raised to $20 from $15 at Lake Street
03/15/21 Lake Street
Bioceres initiated with a Buy at Lake Street
CNSP CNS Pharmaceuticals
$1.79 /

-0.01 (-0.56%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
DTSS Datasea
$2.65 /

+0.005 (+0.19%)

FLY Fly Leasing
$16.93 /

-0.02 (-0.12%)

04/05/21 Cowen
Fly Leasing downgraded to Market Perform from Outperform at Cowen
04/01/21 JPMorgan
JPMorgan downgrades Fly Leasing to Underweight after takeover announcement
04/01/21 JPMorgan
Fly Leasing downgraded to Underweight from Overweight at JPMorgan
03/19/21 Deutsche Bank
Fly Leasing price target raised to $13 from $10 at Deutsche Bank
GOVX GeoVax Labs
$5.21 /

-0.01 (-0.19%)

11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
GBOX GreenBox
$8.35 /

+0.11 (+1.33%)

PFMT Performant Financial
$2.10 /

-0.01 (-0.47%)

MNTX Manitex
$7.28 /

+ (+0.00%)

11/19/20 Roth Capital
Manitex resumed with a Buy at Roth Capital
MACE Mace Security
/

+

KTRA Kintara Therapeutics
$1.30 /

+0.015 (+1.17%)

09/14/20 Aegis
Kintara Therapeutics initiated with a Buy at Aegis
NSPR InspireMD
$4.67 /

+0.09 (+1.97%)

10/16/20 Alliance Global Partners
InspireMD initiated with a Buy at Alliance Global Partners
SING SinglePoint
/

+

TNXP Tonix Pharmaceuticals
$1.06 /

-0.005 (-0.47%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
URG Ur-Energy
$1.45 /

+0.05 (+3.58%)

04/19/21 Alliance Global Partners
Ur-Energy initiated with a Buy at Alliance Global Partners
03/26/21 H.C. Wainwright
Ur-Energy price target raised to $2.10 from $1.40 at H.C. Wainwright
12/14/20 Cantor Fitzgerald
Cameco downgraded to Hold from Buy at Cantor Fitzgerald
VLON Vallon Pharmaceuticals
$3.67 /

+0.03 (+0.82%)

SPI SPI Energy
$5.35 /

+0.22 (+4.29%)

EDT Entergy Texas
/

+

XBIO Xenetic
$1.68 /

+0.01 (+0.60%)

01/11/21 H.C. Wainwright
Xenetic price target raised to $5 from $2 at H.C. Wainwright
VLON Vallon Pharmaceuticals
$3.67 /

+0.03 (+0.82%)

TNXP Tonix Pharmaceuticals
$1.06 /

-0.005 (-0.47%)

KTRA Kintara Therapeutics
$1.30 /

+0.015 (+1.17%)

FLY Fly Leasing
$16.93 /

-0.02 (-0.12%)

BIOX Bioceres
$15.76 /

+0.41 (+2.67%)

AEZS Aeterna Zentaris
/

+

  • 17
    Feb
  • 17
    Feb
  • 04
    Feb
  • 10
    Feb
  • 23
    Dec
  • 01
    Oct
  • 25
    Sep
GBOX GreenBox
$8.35 /

+0.11 (+1.33%)

FLY Fly Leasing
$16.93 /

-0.02 (-0.12%)

VLON Vallon Pharmaceuticals
$3.67 /

+0.03 (+0.82%)

TNXP Tonix Pharmaceuticals
$1.06 /

-0.005 (-0.47%)

SPI SPI Energy
$5.35 /

+0.22 (+4.29%)

GBOX GreenBox
$8.35 /

+0.11 (+1.33%)

FLY Fly Leasing
$16.93 /

-0.02 (-0.12%)

BIOX Bioceres
$15.76 /

+0.41 (+2.67%)

SPI SPI Energy
$5.35 /

+0.22 (+4.29%)

PFMT Performant Financial
$2.10 /

-0.01 (-0.47%)

GBOX GreenBox
$8.35 /

+0.11 (+1.33%)

BIOX Bioceres
$15.76 /

+0.41 (+2.67%)

AEZS Aeterna Zentaris
/

+

Conference/Events
Maxim Group to hold a virtual conference » 04:55
03/18/21
03/18
04:55
03/18/21
04:55
CNSP

CNS Pharmaceuticals

$2.85 /

+0.18 (+6.74%)

, KTRA

Kintara Therapeutics

$2.14 /

-0.02 (-0.93%)

, PSTV

Plus Therapeutics

$2.85 /

+0.08 (+2.89%)

, TCON

Tracon Pharmaceuticals

$9.30 /

+0.2 (+2.20%)

, MDNA

Medicenna Therapeutics

$4.01 /

-0.01 (-0.25%)

, INO

Inovio

$10.53 /

+0.07 (+0.67%)

, ONCR

Oncorus

$16.33 /

-0.485 (-2.88%)

, GOVX

GeoVax Labs

$5.73 /

+0.39 (+7.30%)

, HTBX

Heat Biologics

$8.66 /

+0.3 (+3.59%)

, SLS

Sellas Life Sciences

$11.67 /

+1.25 (+12.00%)

, PLSE

Pulse Biosciences

$25.60 /

-0.4 (-1.54%)

, SRTS

Sensus Healthcare

$4.39 /

-0.02 (-0.45%)

, VERO

Venus Concept

$2.77 /

+0.18 (+6.95%)

, SOLY

Soliton

$16.86 /

-0.67 (-3.82%)

, CLXPF

Cybin

$0.00 /

+ (+0.00%)

, MMED

Midas Medici

$0.00 /

+ (+0.00%)

, CHFS

CHF Solutions

$6.19 /

-1.15 (-15.67%)

, ECOR

electroCore

$2.19 /

+0.095 (+4.53%)

, BIOL

Biolase

$1.01 /

+0.0553 (+5.79%)

, AEMD

Aethlon Medical

$2.25 /

-0.06 (-2.60%)

, ZSAN

Zosano Pharma

$1.47 /

+0.14 (+10.53%)

, NLSP

NLS Pharmaceutics

$4.51 /

+0.15 (+3.44%)

, CYTH

Cyclo Therapeutics

$12.80 /

+0.41 (+3.31%)

, MNPR

Monopar Therapeutics

$7.38 /

-0.11 (-1.47%)

Inaugural Emerging Growth…

Inaugural Emerging Growth Virtual Conference 2021 will be held on March 17-19.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

SOLY Soliton
$16.86 /

-0.67 (-3.82%)

SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

PSTV Plus Therapeutics
$2.85 /

+0.08 (+2.89%)

PLSE Pulse Biosciences
$25.60 /

-0.4 (-1.54%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

NLSP NLS Pharmaceutics
$4.51 /

+0.15 (+3.44%)

MNPR Monopar Therapeutics
$7.38 /

-0.11 (-1.47%)

MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

KTRA Kintara Therapeutics
$2.14 /

-0.02 (-0.93%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

GOVX GeoVax Labs
$5.73 /

+0.39 (+7.30%)

ECOR electroCore
$2.19 /

+0.095 (+4.53%)

CYTH Cyclo Therapeutics
$12.80 /

+0.41 (+3.31%)

CNSP CNS Pharmaceuticals
$2.85 /

+0.18 (+6.74%)

CHFS CHF Solutions
$6.19 /

-1.15 (-15.67%)

BIOL Biolase
$1.01 /

+0.0553 (+5.79%)

AEMD Aethlon Medical
$2.25 /

-0.06 (-2.60%)

CNSP CNS Pharmaceuticals
$2.85 /

+0.18 (+6.74%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
KTRA Kintara Therapeutics
$2.14 /

-0.02 (-0.93%)

09/14/20 Aegis
Kintara Therapeutics initiated with a Buy at Aegis
PSTV Plus Therapeutics
$2.85 /

+0.08 (+2.89%)

02/11/21
Fly Intel: Top five analyst initiations
02/11/21 H.C. Wainwright
Plus Therapeutics initiated with a Buy at H.C. Wainwright
01/25/21 Ladenburg
Plus Therapeutics initiated with a Buy at Ladenburg
10/16/20
Fly Intel: Top five analyst initiations
TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
09/17/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $7 from $4 at H.C. Wainwright
MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

12/17/20 Oppenheimer
Medicenna Therapeutics initiated with an Outperform at Oppenheimer
09/10/20 H.C. Wainwright
Medicenna Therapeutics initiated with a Buy at H.C. Wainwright
INO Inovio
$10.53 /

+0.07 (+0.67%)

03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
02/11/21 Oppenheimer
Inovio initiated with an Outperform at Oppenheimer
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

03/16/21
Fly Intel: Top five analyst initiations
03/16/21 Maxim
Oncorus initiated with a Buy at Maxim
11/11/20 Piper Sandler
Oncorus timelines remain on track after Q3 results, says Piper Sandler
10/27/20 Jefferies
Oncorus initiated with a Buy at Jefferies
GOVX GeoVax Labs
$5.73 /

+0.39 (+7.30%)

11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
PLSE Pulse Biosciences
$25.60 /

-0.4 (-1.54%)

03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
02/04/21 H.C. Wainwright
Pulse Biosciences price target raised to $46 from $40 at H.C. Wainwright
01/26/21 H.C. Wainwright
Pulse Biosciences price target raised to $40 from $16 at H.C. Wainwright
SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

03/01/21 H.C. Wainwright
Sensus Healthcare price target raised to $6 from $4 at H.C. Wainwright
02/26/21 Northland
Northland upgrades Sensus Healthcare to Outperform after 'strong' Q4 report
02/26/21 Northland
Sensus Healthcare upgraded to Outperform from Market Perform at Northland
12/16/20 Northland
Sensus Healthcare downgraded to Market Perform on valuation at Northland
VERO Venus Concept
$2.77 /

+0.18 (+6.95%)

12/29/20 BTIG
Venus Concept flying under the radar, says BTIG
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
11/16/20 Oppenheimer
Venus Concept upgraded to Outperform with $4 target at Oppenheimer
SOLY Soliton
$16.86 /

-0.67 (-3.82%)

03/08/21 Maxim
Soliton's multiple 2021 trials to expand its pipeline, says Maxim
02/08/21 Maxim
Soliton price target raised to $25 from $22 at Maxim
02/02/21 Cantor Fitzgerald
Soliton price target raised to $20 from $12 at Cantor Fitzgerald
07/15/20 Cantor Fitzgerald
Soliton initiated with an Overweight at Cantor Fitzgerald
CLXPF Cybin
$0.00 /

+ (+0.00%)

03/15/21 Canaccord
Cybin initiated with a Buy at Canaccord
01/14/21 Stifel
Cybin initiated with a Speculative Buy at Stifel
MMED Midas Medici
$0.00 /

+ (+0.00%)

CHFS CHF Solutions
$6.19 /

-1.15 (-15.67%)

10/21/20 Maxim
CHF Solutions price target lowered to $20 from $45 at Maxim
06/05/20 Maxim
CHF Solutions initiated with a Buy at Maxim
ECOR electroCore
$2.19 /

+0.095 (+4.53%)

10/22/20 Brookline
electroCore initiated with a Buy at Brookline
09/30/20
Fly Intel: Top five analyst initiationsNewPage
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
BIOL Biolase
$1.01 /

+0.0553 (+5.79%)

01/26/21 Maxim
Biolase price target raised to $2 at Maxim on 'strong' preliminary Q4 revenue
10/14/20 Maxim
Biolase initiated with a Buy at Maxim
04/09/20
Biolase supplying ventilators 'highly encouraging,' says Dougherty
AEMD Aethlon Medical
$2.25 /

-0.06 (-2.60%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Maxim
Aethlon Medical initiated with a Buy at Maxim
ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

03/15/21 Maxim
Zosano Pharma price target raised to $2.50 from $1.50 at Maxim
10/22/20 BTIG
Zosano Pharma price target lowered to $2 from $7 at BTIG
10/02/20 H.C. Wainwright
Zosano Pharma price target lowered to $2.50 from $4 at H.C. Wainwright
09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
NLSP NLS Pharmaceutics
$4.51 /

+0.15 (+3.44%)

03/12/21 Brookline
NLS Pharmaceutics initiated with a Buy at Brookline
03/03/21 Maxim
NLS Pharmaceutics initiated with a Buy at Maxim
CYTH Cyclo Therapeutics
$12.80 /

+0.41 (+3.31%)

02/10/21 Maxim
Cyclo Therapeutics price target raised to $25 from $12 at Maxim
12/17/20 Maxim
Cyclo Therapeutics initiated with a Buy at Maxim
MNPR Monopar Therapeutics
$7.38 /

-0.11 (-1.47%)

01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

VERO Venus Concept
$2.77 /

+0.18 (+6.95%)

TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

SOLY Soliton
$16.86 /

-0.67 (-3.82%)

SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

PSTV Plus Therapeutics
$2.85 /

+0.08 (+2.89%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

MNPR Monopar Therapeutics
$7.38 /

-0.11 (-1.47%)

MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

KTRA Kintara Therapeutics
$2.14 /

-0.02 (-0.93%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

ECOR electroCore
$2.19 /

+0.095 (+4.53%)

CHFS CHF Solutions
$6.19 /

-1.15 (-15.67%)

BIOL Biolase
$1.01 /

+0.0553 (+5.79%)

AEMD Aethlon Medical
$2.25 /

-0.06 (-2.60%)

  • 17
    Mar
  • 12
    Feb
  • 29
    Jan
  • 21
    Jan
  • 23
    Dec
  • 22
    Dec
  • 02
    Oct
  • 25
    Sep
  • 01
    Sep
  • 26
    Jun
SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

VERO Venus Concept
$2.77 /

+0.18 (+6.95%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

NLSP NLS Pharmaceutics
$4.51 /

+0.15 (+3.44%)

MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

GOVX GeoVax Labs
$5.73 /

+0.39 (+7.30%)

TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.